( Cimzia Maintained Long-term Response at...)UCB Presents Long-Term CImzia Data in Crohn's Disease,Health

ATLANTA, May 22, 2007 /PRNewswire/ -- UCB announced today that new data presented at Digestive Disease Week 2007 (DDW) demonstrated long-term response and remission in Crohn's disease patients treated with Cimzia (certolizumab pegol), the only Fc-free PEGylated, Fab' fragment anti-TNF.

The study, called PRECiSE 3 (P3), is a long-term open label continuation of the Phase III PRECiSE Program for CIMZIA(TM). Some of the study results presented at DDW are an interim analysis of a patient subgroup that responded continuously to CIMZIA(TM) during an 18-month period. These patients completed the PRECiSE 1 (P1) or PRECiSE 2 (P2) trials, enrolling in P3 at week 26. At week 80, the study showed that more than 85 percent of the patient subgroup who continuously received CIMZIA(TM) 400 mg subcutaneously every four weeks maintained clinical response, with nearly 74 percent of these patients achieving remission. (1) The extension study used the Harvey-Bradshaw Index (HBI)(a) to assess clinical response (defined as a reduction in HBI score of at least three points) and remission (HBI score less than or equal to four points).

Importantly, results reported from P3 indicated that CIMZIA(TM) was well- tolerated throughout the study. The percentage of patients experiencing injection-site reactions and injection-site pain was low (<2%, <1% respectively). (3)

"These study results show robust rates of clinical response and remission during an 18-month period in patients with Crohn's disease," said Stephen Hanauer, M.D., Professor of Medicine and Clinical Pharmacology Chief, Section of Gastroenterology and Nutrition, University of Chicago, and study co-author. "Also, CIMZIA(TM) dosing did not need to be increased over the course of the study."

"These results fortify UCB's commitment to obtai
'"/>